Divis Laboratories Ltd

Divi's Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Divis Laboratories Ltd

₹ 7,314 -0.98%
23 Jul 9:29 a.m.
divislabs.com BSE: 532488 NSE: DIVISLAB
About

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Key Points

Business Overview:[1]
The company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Co. is world’s largest API manufacturer for 10 generic APIs.[3]
b) Custom Synthesis:[4]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[5][6]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Website BSE NSE
  • Market Cap ₹ 1,94,164 Cr.
  • Current Price ₹ 7,314
  • High / Low ₹ 7,438 / 5,636
  • Stock P/E 72.9
  • Book Value ₹ 629
  • Dividend Yield 0.41 %
  • ROCE 22.4 %
  • ROE 16.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.0%

Cons

  • Stock is trading at 11.7 times its book value
  • The company has delivered a poor sales growth of 8.85% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,908 1,730 1,868 1,808 2,259 2,063 2,302 2,297 2,536 2,357 2,660 2,578 2,793
1,419 1,239 1,394 1,317 1,542 1,442 1,573 1,550 1,655 1,614 1,765 1,671 1,850
Operating Profit 489 491 474 491 717 621 729 747 881 743 895 907 943
OPM % 26% 28% 25% 27% 32% 30% 32% 33% 35% 32% 34% 35% 34%
66 80 85 94 79 79 105 82 87 119 146 13 154
Interest 0 0 1 0 2 0 1 0 0 3 8 6 6
Depreciation 87 93 94 95 94 97 98 99 107 112 113 116 120
Profit before tax 468 478 464 490 700 603 735 730 861 747 920 798 971
Tax % 32% 28% 26% 27% 24% 29% 30% 19% 23% 25% 24% 25% 22%
319 345 342 358 531 430 518 594 667 557 696 598 756
EPS in Rs 12.02 13.00 12.88 13.49 20.00 16.20 19.51 22.38 25.13 20.98 26.22 22.53 28.48
Raw PDF
Upcoming result date: 1 August 2026

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
3,084 3,720 4,024 3,816 4,880 5,311 6,799 8,880 7,625 7,665 9,198 10,388
1,914 2,314 2,582 2,558 3,028 3,491 3,971 5,000 5,275 5,486 6,214 6,899
Operating Profit 1,170 1,406 1,441 1,258 1,851 1,820 2,828 3,880 2,350 2,179 2,984 3,489
OPM % 38% 38% 36% 33% 38% 34% 42% 44% 31% 28% 32% 34%
36 92 73 106 155 187 57 109 348 333 348 432
Interest 3 4 3 2 5 7 2 2 2 4 2 24
Depreciation 136 118 123 142 169 186 255 311 342 376 401 461
Profit before tax 1,067 1,375 1,388 1,219 1,833 1,813 2,628 3,677 2,354 2,132 2,929 3,436
Tax % 21% 19% 24% 29% 27% 24% 26% 20% 23% 26% 25% 24%
847 1,111 1,053 870 1,333 1,373 1,955 2,949 1,808 1,576 2,209 2,607
EPS in Rs 31.90 41.84 39.68 32.76 50.20 51.71 73.63 111.07 68.11 59.37 83.21 98.20
Dividend Payout % 31% 24% 25% 31% 32% 31% 27% 27% 44% 50% 36% 30%
Compounded Sales Growth
10 Years: 11%
5 Years: 9%
3 Years: 11%
TTM: 13%
Compounded Profit Growth
10 Years: 9%
5 Years: 6%
3 Years: 14%
TTM: 21%
Stock Price CAGR
10 Years: 20%
5 Years: 9%
3 Years: 26%
1 Year: 11%
Return on Equity
10 Years: 18%
5 Years: 17%
3 Years: 15%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 27 53 53 53 53 53 53 53 53 53 53 53
Reserves 3,535 4,304 5,356 5,907 6,920 7,264 9,218 11,638 12,652 13,431 14,842 16,658
27 42 36 63 106 34 0 0 0 0 2 0
886 566 765 785 961 1,164 1,452 1,617 1,647 1,878 1,927 3,243
Total Liabilities 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 15,362 16,824 19,954
1,309 1,439 1,559 1,996 2,087 2,776 3,699 4,321 4,719 4,737 5,440 6,520
CWIP 218 264 444 120 492 920 711 470 212 778 1,022 2,113
Investments 736 813 1,639 1,897 1,953 979 7 79 84 89 72 76
2,212 2,450 2,568 2,795 3,508 3,839 6,307 8,438 9,337 9,758 10,290 11,245
Total Assets 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 15,362 16,824 19,954

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
822 1,036 1,149 765 964 1,208 1,947 1,910 2,447 1,266 1,650 2,711
-521 -411 -1,137 -476 -684 -81 75 -2,195 -2,707 -268 -803 -2,218
-303 -630 3 -314 -246 -1,091 -34 -532 -796 -798 -797 -802
Net Cash Flow -1 -5 15 -25 34 36 1,988 -817 -1,056 200 50 -309
Free Cash Flow 515 641 773 491 231 26 1,037 1,196 1,975 264 213 195
CFO/OP 88% 92% 101% 82% 78% 91% 91% 65% 124% 75% 83% 102%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 97 95 91 106 96 105 94 106 94 108 113 113
Inventory Days 335 284 291 311 324 299 322 316 329 347 296 331
Days Payable 67 56 103 98 94 99 118 92 88 94 86 106
Cash Conversion Cycle 365 323 280 319 325 305 298 330 335 361 323 338
Working Capital Days 146 165 153 185 173 184 155 178 190 207 193 198
ROCE % 32% 35% 28% 21% 28% 24% 32% 35% 19% 16% 21% 22%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Exports as % of Total Sales
% of total sales

Log in to view insights

Please log in to see hidden values.

Login
Europe Revenue Share
% of sales
North America Revenue Share
% of sales
Top 5 Customers Concentration
% of revenue
Top 5 Products Concentration
% of revenue
US FDA Drug Master Files (DMFs) Filed
count
Total Products in Portfolio
count
Generics as % of Revenue (Product Mix)
% of revenue
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
51.93% 51.92% 51.92% 51.89% 51.89% 51.89% 51.89% 51.88% 51.88% 51.88% 51.88% 51.88%
14.60% 14.85% 14.68% 16.16% 17.25% 17.98% 18.01% 19.74% 19.39% 20.08% 20.29% 20.20%
21.65% 21.78% 22.10% 21.66% 20.98% 20.44% 20.63% 18.96% 19.68% 19.18% 19.13% 19.38%
0.10% 0.10% 0.10% 0.10% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09% 0.00%
11.72% 11.33% 11.19% 10.17% 9.79% 9.58% 9.39% 9.32% 8.96% 8.75% 8.61% 8.54%
No. of Shareholders 3,73,8603,54,4823,47,6292,98,3102,78,8992,80,6012,67,7552,59,8252,49,6342,33,8442,28,0062,26,324

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls